EMN vs KNSA · P/E 21, rev $9.38B vs P/E 53, rev $677.6M
Eastman Chemical Company (EMN) versus Kiniksa Pharmaceuticals Ltd (KNSA) — a side-by-side from cached financials, not a winner call.
Eastman Chemical Company (EMN) is a specialty chemicals company listed on US.
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
Latest reported EMN revenue for 2024-12-31 was $9.38B. Net income was $908.0M. Revenue was up 1.9% from 2023-12-31 to 2024-12-31. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
EMN currently screens at market cap $8.21B and trailing P/E 20.8. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
Not investment advice. Open the EMN and KNSA stock pages for the full models.
Not investment advice.